ABBV Dividend: AbbVie's Yield, History & Dividend Safety Analysis (2025–2026)

AbbVie Inc. (NYSE: ABBV) is one of the most closely followed dividend-paying pharmaceutical companies in the United States. Known for its robust quarterly payouts and multi-decade track record of dividend increases, ABBV consistently attracts income-focused investors seeking both yield and growth. As of February 2026, AbbVie pays an annual dividend of $6.92 per share — a figure that has risen more than 330% since the company's 2013 spinoff from Abbott Laboratories.

This page covers everything income investors need to know about the ABBV dividend: the current yield, complete quarterly history, payout ratio, dividend safety metrics, upcoming ex-dividend dates, and how AbbVie compares to other large-cap pharma dividend payers like JNJ, MRK, and PFE.

Current ABBV Dividend & Yield

AbbVie declared its most recent quarterly cash dividend of $1.73 per share on February 19, 2026, payable on May 15, 2026 to stockholders of record as of April 15, 2026. This translates to an annualized dividend of $6.92 per share.

AbbVie is a member of the prestigious S&P 500 Dividend Aristocrats Index, which requires a minimum of 25 consecutive years of annual dividend increases. When including its heritage as part of Abbott Laboratories, ABBV's unbroken streak extends to 53 years of consecutive dividend growth — a distinction fewer than 70 U.S. companies have ever achieved.

ABBV Dividend History (Quarterly, 2021–2026)

The table below tracks AbbVie's quarterly dividend payments per share, including the declaration date, ex-dividend date, and payment date. Each row reflects one dividend event.

Note: Annual dividend totals — 2021: $5.20 | 2022: $5.64 | 2023: $5.92 | 2024: $6.20 | 2025: $6.56 | 2026 (forward): $6.92

ABBV Dividend Growth Rate Analysis

One of the strongest arguments for holding ABBV as a dividend stock is the company's consistent pace of dividend growth. AbbVie's management has demonstrated a clear policy of returning capital to shareholders through annual increases, even through periods of business transition such as the loss of Humira's exclusivity.

The 10-year CAGR of 12.5% is particularly impressive for a company of AbbVie's scale and market capitalization (above $300 billion). While the pace of increases has moderated in recent years as the company navigates post-Humira revenue diversification, the annual raises have remained consistent and well above the broader S&P 500 dividend growth average.

Payout Ratio & ABBV Dividend Safety

Understanding the Payout Ratio Discrepancy

One of the most commonly misunderstood aspects of the ABBV dividend is its reported payout ratio. On a GAAP (Generally Accepted Accounting Principles) basis, AbbVie's trailing 12-month payout ratio often appears alarmingly high — sometimes exceeding 480%–500%. This is because GAAP earnings have been depressed by large non-cash amortization charges tied to past acquisitions (notably Allergan, acquired for $63 billion in 2020).

However, when measured against adjusted diluted EPS (which excludes amortization and other non-recurring items), the payout ratio looks far more sustainable. AbbVie's adjusted payout ratio for fiscal year 2024 was approximately 61%–66%, which is consistent with comparable large-cap pharma companies.

More importantly, the most relevant safety metric is the free cash flow (FCF) payout ratio:

Upcoming ABBV Ex-Dividend & Payment Dates

To receive the next dividend payment, investors must purchase shares of ABBV before the ex-dividend date. Shares purchased on or after that date will not be entitled to the declared dividend.

AbbVie typically announces the following quarter's dividend in late October or early November. Historically, the ex-dividend date falls around the 13th–16th of January, April, July, and October.

ABBV vs. Pharma Peers: Dividend Comparison

How does ABBV measure up against other large-cap dividend-paying pharmaceutical companies? The table below compares AbbVie's key dividend metrics against Johnson & Johnson (JNJ), Merck (MRK), and Pfizer (PFE) as of early 2026.

Key Takeaways from the Comparison

• ABBV offers a higher yield than JNJ with a significantly faster dividend growth rate, making it compelling for investors who want both current income and dividend expansion.
• PFE's high yield is a warning sign: When a yield spikes due to share price weakness (not rising dividends), the dividend itself may be at risk. Pfizer's adjusted payout ratio, while manageable, reflects a company still rebuilding earnings after the COVID therapy revenue cycle.
• JNJ is the only Dividend King in this peer group (62+ years of consecutive increases), but its lower yield and slower growth rate make ABBV a strong challenger for dividend growth investors.
• MRK offers a comparable yield to ABBV but with lower long-term growth and a shorter track record.

How AbbVie's Business Supports Its Dividend

Understanding why the ABBV dividend has grown so consistently requires understanding the business model underpinning it. AbbVie is a global biopharmaceutical company with operations across immunology, oncology, neuroscience, eye care, and aesthetics. Its ability to generate and grow the dividend connects directly to three structural factors:

1. The Humira-to-Skyrizi/Rinvoq Transition

Humira was once the best-selling drug in the world, generating $20+ billion annually. Following biosimilar competition beginning in 2023, US Humira sales declined roughly 49.5% in 2025. However, AbbVie successfully engineered a transition: its next-generation immunology drugs Skyrizi and Rinvoq together generated approximately $26 billion in combined revenue in 2025, with projected growth to $31+ billion in 2026 — exceeding AbbVie's own prior peak guidance.

2. Diversified Revenue Pipeline

Beyond immunology, AbbVie has expanded into neuroscience (Botox, Vraylar, Vuity) and aesthetics, providing multiple revenue streams that are less correlated with any single therapy's lifecycle. Total 2025 net revenues reached $61.16 billion, an 8.6% increase year-over-year.

3. Strong Free Cash Flow Generation

Perhaps the most important dividend safety factor: AbbVie generated approximately $19.7 billion in free cash flow for the twelve months ending September 2025. Total dividends paid amount to roughly $10–11 billion annually at current rates — representing an FCF coverage ratio comfortably above 1.7x. The company also received a Moody's credit upgrade to A2 in February 2026, affirming the improving credit profile.

Risks to the ABBV Dividend

No dividend is guaranteed. Income investors evaluating ABBV should assess the following risk factors carefully before relying on the payout for portfolio income:

1. Drug Concentration Risk

While Skyrizi and Rinvoq are growing rapidly, they represent a high proportion of total immunology revenue. Any unexpected clinical setbacks, safety concerns, or new competitive therapies in plaque psoriasis, inflammatory bowel disease, or rheumatoid arthritis could materially impact revenue projections.

2. Regulatory & Patent Cliff Risk

Skyrizi and Rinvoq will eventually face their own patent expiries. Although this is not an immediate concern (their exclusivity extends well into the 2030s), failure to advance the next-generation pipeline could weaken the company's long-term dividend growth capacity.

3. High Debt Load from Allergan Acquisition

AbbVie carries a significant debt balance from its $63 billion acquisition of Allergan in 2020. While the company has been paying it down steadily, elevated interest expense is a recurring cost that competes with cash available for dividends and share buybacks. Rising interest rates could increase refinancing costs.

4. High GAAP Payout Ratio Optics

The GAAP payout ratio above 480% can create negative headlines and mislead analysts or algorithmic screening tools. While this is a non-cash amortization issue that does not reflect actual cash earnings power, it can cause short-term volatility and misunderstandings about dividend sustainability.

5. Macroeconomic Sensitivity

A broader economic downturn, pharmaceutical pricing reform legislation (including continued Medicare drug negotiation under the Inflation Reduction Act), or sudden stock market contraction could pressure ABBV's share price and create dividend yield distortions.

How to Evaluate ABBV as a Dividend Investment

If you are considering ABBV for a dividend-focused portfolio, here is a structured framework for evaluating its suitability:

Step 1 — Evaluate Yield in Context

A yield of ~3.0–3.1% from an S&P 500 Dividend Aristocrat is meaningfully higher than the S&P 500 average yield of approximately 1.3–1.5%. However, compare this yield against the risk-free rate (10-year U.S. Treasury). If Treasuries yield 4.5%, ABBV's yield premium is thin — meaning investors are accepting lower relative income in exchange for dividend growth potential and equity upside.

Step 2 — Use FCF, Not GAAP EPS, for Safety Analysis

Ignore the GAAP payout ratio. Instead, divide total dividends paid ($10–11B annually) by trailing free cash flow (~$19.7B). An FCF coverage ratio above 1.5x implies a well-protected dividend. AbbVie currently clears this threshold comfortably.

Step 3 — Monitor the Pipeline & Skyrizi/Rinvoq Trajectory

Check quarterly earnings for combined Skyrizi + Rinvoq revenue growth. If these two drugs maintain their combined double-digit growth trajectory, AbbVie's FCF should remain robust enough to sustain and continue growing the dividend.

Step 4 — Watch the Debt Paydown

Track long-term debt reduction each quarter. Declining debt means lower interest expense and more cash available for dividend raises and buybacks.

Step 5 — Compare Against Alternatives Regularly

ABBV's dividend appeal shifts with market conditions. Compare it periodically against peers (JNJ, MRK), dividend ETFs (like VIG or NOBL), and income-generating alternatives. For more healthcare sector context, see InvestSnips' coverage of S&P 500 Healthcare Stocks and our Top 10 Dividend Stocks to Watch.

Summary & Takeaways

AbbVie occupies a rare position in the pharma dividend landscape: a company that combines a meaningful current yield, a verified long-term growth track record, and a credible post-Humira growth story underpinned by two blockbuster immunology drugs. For income investors focused on dividend growth, ABBV merits serious consideration — with appropriate attention paid to its drug pipeline concentration and debt position.

For broader context on pharma and healthcare sector investing, explore InvestSnips' data on Healthcare Stocks in the S&P 500, browse our full S&P 500 Company List, or review our Top Dividend Stocks to Watch for comparative context. Investors interested in sector exposure rather than single stocks may also wish to review our guide on Large-Cap Stocks.

Frequently Asked Questions About the ABBV Dividend